In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...Read More
Type of non Hodgkin’s lymphoma-Other-Burkitt lymphoma Posts on Medivizor
How effective and safe is high-dose chemotherapy and stem cell transplant for children with lymphoma?
In a nutshell This study examined the effectiveness and safety of high-dose chemotherapy and stem cell transplants for children with lymphoma. The study showed that the combination treatment was very effective but that the dose may need to be adjusted for some patients. Some background Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) have very...Read More
In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...Read More
In a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...Read More
Searching for participants to try a new combination of targeted therapy for relapsed or non-responsive B-cell lymphomas.
In a nutshell This study is investigating the effectiveness of a new combination of treatments, nivolumab (Opdivo) and varlilumab (CDX-1127), for non-responsive, aggressive B-cell lymphomas. The main outcome that will be measured is the proportion of patients that respond to treatment (overall response rate). This trial is recruiting in the US. The...Read More
In a nutshell This study investigated the long-term survival outcomes of patients with stage 1 non-Hodgkin’s lymphoma (NHL). This study concluded that these patients have favorable outcomes but may need follow-up after 5 years of remission (no cancer recurrence). Some background Most patients with early-stage (stage 1 – 2) NHL tend to have...Read More
In a nutshell This study looked at the effectiveness of rituximab (Rituxan)-containing chemotherapy in the treatment of patients with B-cell lymphoma who are overweight. Researchers found that overweight patients treated with rituximab-containing treatment have improved outcomes. Some background B-cell lymphoma is a cancer of the immune system....Read More
In a nutshell This study looked at the impact of rituximab treatment and gene mutations on the outcomes for elderly patients who did not respond to first line chemotherpy. The study concluded that patients who experienced treatment failure after first line rituximab and chemotherapy had poor outcomes, but rituximab improved patient outcomes when...Read More
In a nutshell This study looked at the impact being overweight or obese had on outcomes for elderly patients with B-cell lymphomas. The study concluded that female patients who were obese had worse outcomes than those who were not obese. Some background Being overweight or obese can have negative effects on health. People who are obese have...Read More